Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Charlottesville, Virginia 22908


Purpose:

RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. PURPOSE: This clinical trial is studying how well vaccine therapy works in treating patients with stage IIB, stage III, or stage IV colorectal cancer.


Study summary:

OBJECTIVES: - Determine whether vaccination comprising HER-2-neu and carcinoembryonic antigen synthetic peptides, sargramostim (GM-CSF), and Montanide ISA-51 causes an immune response in patients with stage IIB, III, or IV colorectal cancer. - Determine the safety of this regimen in these patients. OUTLINE: Patients receive vaccination comprising HER-2-neu and carcinoembryonic antigen synthetic peptides, sargramostim (GM-CSF), and Montanide ISA-51 on days 1, 8, and 15. On day 22, patients undergo removal of the lymph node into which the vaccination site drains to determine whether the immune system is responding to the vaccine. PROJECTED ACCRUAL: A maximum of 15 patients will be accrued for this study.


Criteria:

DISEASE CHARACTERISTICS: - Diagnosis of colorectal cancer - Stage IIB, III, or IV disease - HLA-A2- or -A3-positive PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-1 Life expectancy - Not specified Hematopoietic - Absolute neutrophil count > 1,000/mm^3 - Hemoglobin > 9 g/dL - Platelet count > 100,000/mm^3 Hepatic - Liver function tests ≤ 2.5 times upper limit of normal (ULN) Renal - Creatinine ≤ 1.5 times ULN Cardiovascular - No New York Heart Association class III or IV heart disease Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No known or suspected allergies to any component of the study drug - No active connective tissue disease requiring medications - No systemic autoimmune disease with visceral involvement - No uncontrolled diabetes - No other severe autoimmune disease - No medical contraindication or potential problem that would preclude study compliance PRIOR CONCURRENT THERAPY: Biologic therapy - More than 30 days since prior immunotherapy - More than 30 days since prior growth factors - More than 30 days since prior allergy shots - No prior vaccination with any study peptides for malignancy Chemotherapy - More than 30 days since prior chemotherapy Endocrine therapy - More than 30 days since prior steroids Radiotherapy - More than 30 days since prior radiotherapy Surgery - More than 30 days since prior surgery Other - At least 30 days, but ≤ 24 months, since prior therapy for colorectal cancer - No concurrent illegal drug use


NCT ID:

NCT00091286


Primary Contact:

Study Chair
Charles M. Friel, MD
University of Virginia


Backup Contact:

N/A


Location Contact:

Charlottesville, Virginia 22908
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: December 13, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.